Stock Taper
EARNINGS CALL ARCHIVE 2 CALLS ON FILE
STLN — Starling Oncology, Inc.
NASDAQ
FULL STOCK PAGE →

Q1 2026 Earnings Call Summary

MAY 7, 2026
REVENUE
$147.4M +3.9%
NET MARGIN
-1.7% +3.6 PTS
EPS
-$0.02 +66.7%
FREE CASH FLOW
-$3.3M -249.9%

No summary has been written for this call yet.